Deficit spending

The UK’s tiny houses are woefully ill-prepared for an ageing population

Retrieved on: 
Thursday, February 15, 2024

Most adults in later life experience some form of ill health, such as arthritis, cognitive impairment, heart problems or issues with hearing and vision.

Key Points: 
  • Most adults in later life experience some form of ill health, such as arthritis, cognitive impairment, heart problems or issues with hearing and vision.
  • The problem is that the UK housing stock is nowhere near ready to cater to this need.
  • And yet, there were more than 20,000 people on English local authority waiting lists for wheelchair and accessible homes.

The impact of poor housing

  • And size matters: the smaller the house, the more difficult it is for those people with disabilities to move around and live fulfilled lives.
  • As journalists Melissa York and Georgia Lambert put it in 2023:
    Poor quality housing costs the NHS £1.4 billion a year, yet the relationship between housing and health is rarely acknowledged.
  • Poor quality housing costs the NHS £1.4 billion a year, yet the relationship between housing and health is rarely acknowledged.
  • Poor housing is routinely cited as a major cause.

Why we need supportive housing design

  • Built environment professionals, including architects, stress the importance of reimagining housing design by establishing Part M Clause 2 (category 2) of the Building Regulations as the baseline to better support healthy ageing.
  • A 90-year-old great-grandmother can live independently if her home features wide doorways, no-step entrances and a walk-in shower with grab bars.
  • The John Morden Centre in Blackheath, London, illustrates how thoughtful design can support older residents’ quality of life.
  • Of course, ideas need to be put into practice for them to really change the way people live.
  • In construction terms, this means that supportive design needs to be enshrined in building regulations and the wider housing policy.
  • Making such design regulations compulsory would see the housing industry effectively contribute to reducing the burden on the NHS and our social care system.
  • Architects talk about resilient housing to describe homes that are built for the long-term with sustainable healthy ageing in mind.


Faye Sedgewick receives funding from Innovate UK and is a member of the Architects Registration Board. Paul Jones receives funding from Innovate UK, Research England, AHRC

Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress

Retrieved on: 
Wednesday, February 14, 2024

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.
  • Revenue: Collaboration revenue from sales of ZURZUVAE was $0.8 million in the fourth quarter of 2023, the first quarter of sales.
  • Net Loss: Net loss was $32.7 million for the fourth quarter of 2023 compared to $147.1 million for the same period in 2022.
  • ET to review its fourth quarter and full year 2023 financial results and discuss recent corporate updates.

Alzheimer's Research & Therapy: Linus Health Digital Clock and Recall Test Detects Early Cognitive Impairment in Over 80% of Patients Who Were Misclassified in Commonly Used Paper-Based Test

Retrieved on: 
Tuesday, February 13, 2024

BOSTON, Feb. 13, 2024 /PRNewswire/ -- A proprietary cognitive assessment from Linus Health, a digital health company focused on enabling early detection of Alzheimer's and other dementias, outperforms the most commonly used paper-based assessment in detecting early mild cognitive impairment and dementia and with less ethnic and racial bias, according to a peer-reviewed study recently published in the prestigious medical journal Alzheimer's Research & Therapy.

Key Points: 
  • The body of research confirms the most recent findings that the DCR outperforms a commonly used traditional cognitive test, the MMSE, in detecting early signs of cognitive impairment, and is more accurate overall in classifying mild cognitive impairment and mild dementia.
  • More than 80% of Americans are unfamiliar with mild cognitive impairment, which can be an early stage of Alzheimer's Disease, according to the Alzheimer's Association.
  • Symptoms are also not always noticeable, leading to delayed screenings and potentially greater risk to patients' brain health.
  • In contrast, the DCR was able to detect cognitive impairment in more than 80% of those the MMSE misclassified.

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

uMotif and MoCA Cognition Bring Modern, Patient-Centric eCOA/ePRO, MoCA Test and New XpressO Mobile App to Clinical Trials, Real-World Studies for CNS-Related Conditions

Retrieved on: 
Monday, February 12, 2024

BOSTON and LONDON, Feb. 12, 2024 /PRNewswire-PRWeb/ -- uMotif – one of the clinical research technology market's fastest-growing companies – and MoCA Cognition, creators of the leading test for early cognitive impairment detection – are collaborating to make it easier for sponsors and CROs to capture quality cognitive function and eCOA/ePRO data for CNS research.

Key Points: 
  • The company continues to deepen its portfolio across CNS through its partnership with MoCA Cognition, whose MoCA Test (Montreal Cognitive Assessment) was ranked No.
  • MoCA Cognition CEO and Neurologist Dr. Ziad Nasreddine created the MoCA Test in 1996 to help clinicians and researchers rapidly scan multiple cognitive domains and detect impairment.
  • The standard MoCA test is administered to patients, and can be uploaded into the uMotif platform for central rating and review.
  • Solutions using the standard MoCA test and the uMotif platform are available for immediate deployment.

Gut microbiome: meet Asaccharobacter celatus – the brain health bug

Retrieved on: 
Friday, February 9, 2024

Research over recent years also suggests our gut bacteria may have a role in helping us maintain our brain health as we age.

Key Points: 
  • Research over recent years also suggests our gut bacteria may have a role in helping us maintain our brain health as we age.
  • My own preliminary research suggests one gut bug in particular called Asaccharobacter celatus (A celatus) could be useful.

Cognitive impairment and dementia

  • Worryingly, this often progresses to more severe impairment of brain function known as dementia.
  • Dementia affects more than 55 million people around the world, and projections suggest this number will increase to 82 million by 2030.

How gut bacteria could help

  • The bacteria in our gut perform functions that benefit our overall health.
  • A celatus, along with certain other bacteria, is capable of producing a compound known as equol.
  • These bacteria make equol from a compound called daidzein, which is found in soy products including soy milk, tofu and tempeh.
  • In many cases, we can influence the make-up of our gut bacteria through our diet, and this appears to be true for A celatus.
  • Read more:
    Gut bacteria rewind ageing brain in mice

    However, other research has shown consumption of soy foods in the diet has no effect on cognitive function.

  • All this suggests that, alongside the bacteria, we already have in our gut microbiome, what we eat could be equally important.

My research

  • This relates to complex cognitive tasks we perform daily, including doing maths in our head, or reorganising the day’s tasks in our mind when something unexpectedly changes.
  • This research appears promising, but we need more evidence to confirm the potential benefits of both A celatus bacteria and soy foods in helping older people maintain their brain health as they age.
  • Each week we will look at a different microbe and bring you the most up-to-date research on them.
  • Nathan Nuzum currently works at University College Cork as part of APC Microbiome and receives funding from the European Union’s Horizon 2020 Research and Innovation Programme under the INSPIRE COFUND Marie Skłodowska Curie grant agreement No.
  • The unpublished/original work referred to in this article was conducted at Deakin University as part of Dr. Nathan Nuzum's PhD.
  • Dr. Nuzum's PhD supervisors for this work includes his primary supervisor Dr. Helen Macpherson, and his co-supervisors (in alphabetical order) Drs.

Caron Treatment Centers Expands Its Neurorestorative Health Care Services

Retrieved on: 
Thursday, February 8, 2024

Caron Treatment Centers , a nonprofit behavioral healthcare leader for almost 70 years dedicated to treatment, research, prevention and addiction medical education, announces the expansion of its groundbreaking Neurorestorative Health Care services provided at The Keele Medical Center in Delray Beach, Fl.

Key Points: 
  • Caron Treatment Centers , a nonprofit behavioral healthcare leader for almost 70 years dedicated to treatment, research, prevention and addiction medical education, announces the expansion of its groundbreaking Neurorestorative Health Care services provided at The Keele Medical Center in Delray Beach, Fl.
  • “We’re excited to share this expertise more broadly and expand our Neurorestorative Health Care offerings to help more individuals optimize their brain health.”
    Individuals interested in more information about Caron’s 10-day Neurocognitive Assessment or its Neurorestorative Health Care can visit caron.org/neuro-assessment or call 877-369-0109.
  • Caron Treatment Centers is an internationally recognized nonprofit dedicated to addiction and behavioral healthcare treatment, research, prevention, and addiction medicine education.
  • Caron also provides concierge signature treatment for executives, healthcare professionals and older adults and offers Neurorestorative Health Care at our Keele Medical Center in Palm Beach County, Fl.

Organizations Unite to Improve Brain Health

Retrieved on: 
Thursday, February 8, 2024

This initiative brings together leaders from some of the biggest organizations in America to create environments that promote brain health for employees, communities, and consumers as brain health conditions rise, including Alzheimer’s and dementia.

Key Points: 
  • This initiative brings together leaders from some of the biggest organizations in America to create environments that promote brain health for employees, communities, and consumers as brain health conditions rise, including Alzheimer’s and dementia.
  • Among other action items, the Collaborative is working with HERO Health and Mercer to develop a Brain Health Best Practices Scorecard.
  • “We are excited to be working alongside so many innovative organizations in the Collaborative to advance practices and programs in the workplace and throughout communities at large to help optimize brain health,” said Sarah Lenz Lock, Senior Vice President for Policy and Brain Health and Executive Director of the Global Council on Brain Health.
  • For more information about the Business Collaborative for Brain Health and the Brain Health Best Practices Scorecard, click here .

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease

Retrieved on: 
Thursday, February 8, 2024

Alector and GSK are co-developing and will be co-commercializing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing and will be co-commercializing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • We look forward to continuing the development of AL101 in this Phase 2 trial with our partner GSK who is operationalizing the trial.
  • The primary endpoint of the study is disease progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB).
  • The study results demonstrated that the PK and PD profile supported the progression to Phase 2 clinical trials for more prevalent neurodegenerative conditions, such as AD and Parkinson’s disease.

Vandria Awarded €3.8M in Prestigious Innosuisse and Eurostars Grants to Advance Innovative Drug Programs for Age-Related Diseases of the CNS and Muscle

Retrieved on: 
Thursday, February 8, 2024

Vandria contributes CHF 4.6M to the grant alongside the CHF 2.5M non-dilutive funding from Innosuisse.

Key Points: 
  • Vandria contributes CHF 4.6M to the grant alongside the CHF 2.5M non-dilutive funding from Innosuisse.
  • Innosuisse is the Swiss Innovation Agency that helps to fund science-based pre-commercial projects of start-ups with significant innovation potential.
  • Klaus Dugi, MD, CEO of Vandria, said, “These prestigious grant awards are an endorsement of the science and the team behind Vandria.
  • The Eurostars grant significantly helps us to advance, in parallel, our program in muscle disease.